UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation

NYSE:UTI • US9139151040

Current stock price

36.1 USD
-0.91 (-2.46%)
At close:
36.1 USD
0 (0%)
After Hours:

This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. UTI Profitability Analysis

1.1 Basic Checks

  • UTI had positive earnings in the past year.
  • In the past year UTI had a positive cash flow from operations.
  • Each year in the past 5 years UTI has been profitable.
  • Each year in the past 5 years UTI had a positive operating cash flow.
UTI Yearly Net Income VS EBIT VS OCF VS FCFUTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M

1.2 Ratios

  • UTI's Return On Assets of 6.44% is fine compared to the rest of the industry. UTI outperforms 73.97% of its industry peers.
  • With a decent Return On Equity value of 15.98%, UTI is doing good in the industry, outperforming 75.34% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 8.69%, UTI is in the better half of the industry, outperforming 76.71% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for UTI is significantly below the industry average of 15.17%.
  • The last Return On Invested Capital (8.69%) for UTI is above the 3 year average (7.27%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROIC 8.69%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
UTI Yearly ROA, ROE, ROICUTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

1.3 Margins

  • With a decent Profit Margin value of 6.28%, UTI is doing good in the industry, outperforming 65.75% of the companies in the same industry.
  • UTI's Profit Margin has improved in the last couple of years.
  • The Operating Margin of UTI (8.38%) is better than 67.12% of its industry peers.
  • In the last couple of years the Operating Margin of UTI has grown nicely.
  • With a Gross Margin value of 49.62%, UTI perfoms like the industry average, outperforming 54.79% of the companies in the same industry.
  • UTI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
UTI Yearly Profit, Operating, Gross MarginsUTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. UTI Health Analysis

2.1 Basic Checks

  • UTI has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for UTI has been increased compared to 1 year ago.
  • UTI has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for UTI has been reduced compared to a year ago.
UTI Yearly Shares OutstandingUTI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
UTI Yearly Total Debt VS Total AssetsUTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 4.00 indicates that UTI is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.00, UTI is in the better half of the industry, outperforming 73.97% of the companies in the same industry.
  • The Debt to FCF ratio of UTI is 6.28, which is on the high side as it means it would take UTI, 6.28 years of fcf income to pay off all of its debts.
  • UTI's Debt to FCF ratio of 6.28 is fine compared to the rest of the industry. UTI outperforms 71.23% of its industry peers.
  • A Debt/Equity ratio of 0.29 indicates that UTI is not too dependend on debt financing.
  • UTI's Debt to Equity ratio of 0.29 is in line compared to the rest of the industry. UTI outperforms 58.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Altman-Z 4
ROIC/WACC0.99
WACC8.74%
UTI Yearly LT Debt VS Equity VS FCFUTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
  • UTI has a Current ratio of 1.14. This is comparable to the rest of the industry: UTI outperforms 45.21% of its industry peers.
  • UTI has a Quick Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
  • UTI has a Quick ratio (1.14) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.14
UTI Yearly Current Assets VS Current LiabilitesUTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. UTI Growth Analysis

3.1 Past

  • The earnings per share for UTI have decreased by 0.00% in the last year.
  • UTI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 65.96% yearly.
  • Looking at the last year, UTI shows a quite strong growth in Revenue. The Revenue has grown by 12.59% in the last year.
  • The Revenue has been growing by 22.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%

3.2 Future

  • UTI is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.89% yearly.
  • Based on estimates for the next years, UTI will show a quite strong growth in Revenue. The Revenue will grow by 8.84% on average per year.
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
UTI Yearly Revenue VS EstimatesUTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
UTI Yearly EPS VS EstimatesUTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

2

4. UTI Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 37.22, UTI can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Earnings ratio of UTI is on the same level as its industry peers.
  • UTI's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.35.
  • A Price/Forward Earnings ratio of 39.31 indicates a quite expensive valuation of UTI.
  • The rest of the industry has a similar Price/Forward Earnings ratio as UTI.
  • UTI is valuated expensively when we compare the Price/Forward Earnings ratio to 22.61, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 37.22
Fwd PE 39.31
UTI Price Earnings VS Forward Price EarningsUTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • UTI's Enterprise Value to EBITDA ratio is in line with the industry average.
  • UTI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. UTI is cheaper than 60.27% of the companies in the same industry.
Industry RankSector Rank
P/FCF 123.07
EV/EBITDA 18.06
UTI Per share dataUTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The decent profitability rating of UTI may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.56
EPS Next 2Y-10.25%
EPS Next 3Y5.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UTI Dividend Analysis

5.1 Amount

  • UTI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UTI Fundamentals: All Metrics, Ratios and Statistics

UNIVERSAL TECHNICAL INSTITUT

NYSE:UTI (3/31/2026, 7:13:49 PM)

After market: 36.1 0 (0%)

36.1

-0.91 (-2.46%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04
Earnings (Next)05-05
Inst Owners97.17%
Inst Owner Change7.31%
Ins Owners2.7%
Ins Owner Change3.59%
Market Cap1.99B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (6.43%)
Short Float %6.53%
Short Ratio4.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)0.64%
EPS NQ rev (1m)-128.6%
EPS NQ rev (3m)-103.86%
EPS NY rev (1m)0.72%
EPS NY rev (3m)0.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.41%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.22%
Valuation
Industry RankSector Rank
PE 37.22
Fwd PE 39.31
P/S 2.32
P/FCF 123.07
P/OCF 25.64
P/B 5.91
P/tB 6.93
EV/EBITDA 18.06
EPS(TTM)0.97
EY2.69%
EPS(NY)0.92
Fwd EY2.54%
FCF(TTM)0.29
FCFY0.81%
OCF(TTM)1.41
OCFY3.9%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.56
Graham Number11.54
Profitability
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROCE 11.63%
ROIC 8.69%
ROICexc 11.82%
ROICexgc 13.27%
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
FCFM 1.89%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Debt/EBITDA 0.93
Cap/Depr 181.06%
Cap/Sales 7.17%
Interest Coverage 13.88
Cash Conversion 73.39%
Profit Quality 30.06%
Current Ratio 1.14
Quick Ratio 1.14
Altman-Z 4
F-Score7
WACC8.74%
ROIC/WACC0.99
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.9%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%

UNIVERSAL TECHNICAL INSTITUT / UTI Fundamental Analysis FAQ

What is the fundamental rating for UTI stock?

ChartMill assigns a fundamental rating of 5 / 10 to UTI.


What is the valuation status for UTI stock?

ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.


What is the profitability of UTI stock?

UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.


What is the valuation of UNIVERSAL TECHNICAL INSTITUT based on its PE and PB ratios?

The Price/Earnings (PE) ratio for UNIVERSAL TECHNICAL INSTITUT (UTI) is 37.22 and the Price/Book (PB) ratio is 5.91.


Can you provide the expected EPS growth for UTI stock?

The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.